Jennifer J Mueller1, Amelia Kelly1, Qin Zhou2, Alexia Iasonos2, Kara Long Roche3, Yukio Sonoda3, Roisin E O'Cearbhaill4, Oliver Zivanovic3, Dennis S Chi3, Ginger J Gardner5. 1. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA. 4. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. 5. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY, USA. Electronic address: gardnerg@mskcc.org.
Abstract
OBJECTIVES: Intraperitoneal (IP)-based chemotherapy following primary debulking surgery (PDS), although associated with substantial toxicity, is supported by a strong evidence base. We sought to determine feasibility and outcomes of IP chemotherapy after interval debulking surgery (IDS) among patients deemed ineligible for PDS. METHODS: We identified all patients with high-grade, stage III/IV ovarian cancer treated at our institution with neoadjuvant chemotherapy (NACT) followed by IDS and postoperative chemotherapy from 1/2008-5/2013. IP and intravenous (IV) regimens were defined; demographic and clinical data were analyzed using appropriate statistics. RESULTS: Of 128 evaluable patients, 118 (92%) achieved ≤1cm residual disease at IDS and 74 (58%) achieved a complete gross resection (CGR). An IP port was placed in 54/128 patients (42%), with 89% port utilization. Forty-eight (38%) of 128 patients received IP chemotherapy, 17 (13%) weekly IV paclitaxel/q3week carboplatin, and 63 (49%) q3week IV carboplatin/paclitaxel. Patients completed a median of 3 IP cycles (range, 2-6), with 3 (5.5%) of 54 ports removed due to complications. Overall survival (OS) for patients with a CGR treated with IP and weekly IV chemotherapy was 53.2months (range, 24.7-NE), and 44.2months (range, 30.2-NE) with any visible residual disease (p<0.001). Median OS was 53.2months (range, 44.5-NE) for IP-, not reached for weekly IV-, and 34.2months (range, 27.5-49.8) for q3week IV-treated patients (p=0.1). CONCLUSIONS: Patients administered IP after IDS had a high rate of successful port utilization, with few regimen switches. Oncologic outcomes were optimal in patients with a CGR at IDS, regardless of chemotherapy used.
OBJECTIVES: Intraperitoneal (IP)-based chemotherapy following primary debulking surgery (PDS), although associated with substantial toxicity, is supported by a strong evidence base. We sought to determine feasibility and outcomes of IP chemotherapy after interval debulking surgery (IDS) among patients deemed ineligible for PDS. METHODS: We identified all patients with high-grade, stage III/IV ovarian cancer treated at our institution with neoadjuvant chemotherapy (NACT) followed by IDS and postoperative chemotherapy from 1/2008-5/2013. IP and intravenous (IV) regimens were defined; demographic and clinical data were analyzed using appropriate statistics. RESULTS: Of 128 evaluable patients, 118 (92%) achieved ≤1cm residual disease at IDS and 74 (58%) achieved a complete gross resection (CGR). An IP port was placed in 54/128 patients (42%), with 89% port utilization. Forty-eight (38%) of 128 patients received IP chemotherapy, 17 (13%) weekly IV paclitaxel/q3week carboplatin, and 63 (49%) q3week IV carboplatin/paclitaxel. Patients completed a median of 3 IP cycles (range, 2-6), with 3 (5.5%) of 54 ports removed due to complications. Overall survival (OS) for patients with a CGR treated with IP and weekly IV chemotherapy was 53.2months (range, 24.7-NE), and 44.2months (range, 30.2-NE) with any visible residual disease (p<0.001). Median OS was 53.2months (range, 44.5-NE) for IP-, not reached for weekly IV-, and 34.2months (range, 27.5-49.8) for q3week IV-treated patients (p=0.1). CONCLUSIONS:Patients administered IP after IDS had a high rate of successful port utilization, with few regimen switches. Oncologic outcomes were optimal in patients with a CGR at IDS, regardless of chemotherapy used.
Authors: Deborah K Armstrong; Brian Bundy; Lari Wenzel; Helen Q Huang; Rebecca Baergen; Shashikant Lele; Larry J Copeland; Joan L Walker; Robert A Burger Journal: N Engl J Med Date: 2006-01-05 Impact factor: 91.245
Authors: Joan L Walker; Deborah K Armstrong; Helen Q Huang; Jeffrey Fowler; Kenneth Webster; Robert A Burger; Daniel Clarke-Pearson Journal: Gynecol Oncol Date: 2006-01 Impact factor: 5.482
Authors: Usha Menon; Steven J Skates; Sara Lewis; Adam N Rosenthal; Barnaby Rufford; Karen Sibley; Nicola Macdonald; Anne Dawnay; Arjun Jeyarajah; Robert C Bast; David Oram; Ian J Jacobs Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed Journal: N Engl J Med Date: 2010-09-02 Impact factor: 91.245
Authors: M Markman; B N Bundy; D S Alberts; J M Fowler; D L Clark-Pearson; L F Carson; S Wadler; J Sickel Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: Giovanni D Aletti; Eric L Eisenhauer; Antonio Santillan; Allison Axtell; Giacomo Aletti; Christine Holschneider; Dennis S Chi; Robert E Bristow; William A Cliby Journal: Gynecol Oncol Date: 2010-10-08 Impact factor: 5.482
Authors: Saundra S Buys; Edward Partridge; Mark H Greene; Philip C Prorok; Douglas Reding; Thomas L Riley; Patricia Hartge; Richard M Fagerstrom; Lawrence R Ragard; David Chia; Grant Izmirlian; Mona Fouad; Christine C Johnson; John K Gohagan Journal: Am J Obstet Gynecol Date: 2005-11 Impact factor: 8.661
Authors: Amy D Tiersten; P Y Liu; Harriet O Smith; Sharon P Wilczynski; William R Robinson; Maurie Markman; David S Alberts Journal: Gynecol Oncol Date: 2009-01-12 Impact factor: 5.482
Authors: Canan Schumann; Stephanie Chan; Jess A Millar; Yuliya Bortnyak; Katherine Carey; Alex Fedchyk; Leon Wong; Tetiana Korzun; Abraham S Moses; Anna Lorenz; Delany Shea; Olena Taratula; Oleh Khalimonchuk; Oleh Taratula Journal: Nanomedicine Date: 2018-04-07 Impact factor: 5.307
Authors: Orestis Tsonis; Fani Gkrozou; Konstantinos Vlachos; Minas Paschopoulos; Michail C Mitsis; Nikolaos Zakynthinakis-Kyriakou; Stergios Boussios; George Pappas-Gogos Journal: Ann Transl Med Date: 2020-12